Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CareDx Inc    CDNA

CAREDX INC

(CDNA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Glancy Prongay & Murray LLP : Announces Investigation on Behalf of CareDx, Inc. Investors (CDNA)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/16/2019 | 04:52pm EDT

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.

On July 16, 2019, Kerrisdale Capital Research released a report alleging, among other things, that the Company’s diagnostic test, AlloSure, is “fundamentally incapable of identifying the most common type of kidney rejection.” Moreover, the report stated that AlloSure revenues are derived from “protocol usage in clinical testing, which is suffering 20-30% quarterly attrition.”

On this news, shares of CareDx fell as much as 14% during intraday trading, thereby injuring investors.

If you purchased CareDx securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CAREDX INC
08/22AlloSure for Heart Transplant Patients Receives CMS Draft Coverage
GL
08/21CAREDX : Fear of Rejection is Transplant Patient's Top Concern
AQ
08/03Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against ..
BU
08/01CAREDX : 2Q Earnings Snapshot
AQ
08/01CAREDX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
08/01CAREDX, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/01CareDx Reports Second Quarter 2019 Results
GL
07/24CAREDX Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedin..
PR
07/22GLANCY PRONGAY & MURRAY LLP : Continues Investigation on Behalf of CareDx, Inc. ..
BU
07/22Law Offices of Howard G. Smith Continues Investigation on Behalf of CareDx, I..
BU
More news
Financials (USD)
Sales 2019 125 M
EBIT 2019 -24,1 M
Net income 2019 -29,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -33,2x
P/E ratio 2020 -127x
Capi. / Sales2019 7,74x
Capi. / Sales2020 5,69x
Capitalization 966 M
Chart CAREDX INC
Duration : Period :
CareDx Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CAREDX INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 48,80  $
Last Close Price 22,80  $
Spread / Highest target 176%
Spread / Average Target 114%
Spread / Lowest Target 84,2%
EPS Revisions
Managers
NameTitle
Peter K. Maag Chief Executive Officer & Director
Reginald Seeto President & Chief Business Officer
Michael D. Goldberg Independent Chairman
Michael Bell Chief Financial Officer
James P. Yee Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CAREDX INC-9.31%966
GUARDANT HEALTH INC151.77%8 798
GENSCRIPT BIOTECH CORP69.90%4 235
IOVANCE BIOTHERAPEUTICS INC121.47%2 427
INVITAE CORP--.--%2 284
MIRACA HOLDINGS INC.-3.17%1 271